#Taiwan #Taichung #RFID #SAG #LiquidMate O

SAG Introduces LiquidMate O: A New Era in Medication Tracking

SAG, a leading innovator in RFID technology, recently unveiled its latest product, LiquidMate O—a state-of-the-art UHF RFID label designed specifically for item-level traceability of liquid-filled injectable medications. This solution is not just a product launch but a significant leap in the pharmaceutical industry, enhancing the accuracy and efficiency of medication tracking in complex workflows.

The Challenge of Tracking Injectable Medications

Tracking injectable medications has always posed considerable challenges, given the intricacies involved in their storage, handling, and usage within health care settings. Healthcare institutions face substantial losses from expired inventories and misplaced medications. Furthermore, increasing regulatory requirements, especially under the U.S. Drug Supply Chain Security Act (DSCSA), necessitate reliable methods for tracking these critical products.

Innovative Technology Behind LiquidMate O

The LiquidMate O label is built on a unique, patent-pending antenna architecture that enables reliable RFID tagging directly onto vials containing injectable medications. This advancement addresses the historical challenges faced in deploying RFID technology for this application. The item-level tagging capabilities of LiquidMate O have been validated through rigorous testing conducted by AXIA Lab, ensuring its readiness for real-world clinical applications.

Key Features of LiquidMate O

• - One Label for Multiple Formulations: The solution simplifies inventory management by eliminating the need for formulation-specific labels. This capability allows hospitals and pharmaceutical manufacturers to maintain consistent RFID performance across a variety of liquid formulations.
• - True Direct-on-Vial Design: The label is designed specifically for compatibility with industry-standard 10 mL glass vials, optimizing space utilization within pharmaceutical packaging that is often constrained.
• - Proven High-Density Readability: Independent validation confirms that LiquidMate O can achieve a 100% read performance in dense configurations, ensuring that all medications can be accurately tracked, no matter how they are stored or arranged.

Enhancing Efficiency and Patient Safety

By employing this new RFID technology, SAG significantly reduces the complexity often associated with tracking injectables. It eliminates the manual steps typically required in medication dispensing, which not only streamlines operational workflows but also mitigates the risk of errors that can compromise patient safety.

Terry Chiang, CEO of SAG, emphasized the company’s commitment to enhancing healthcare logistics: "With over 20 years of experience in healthcare RFID applications, we recognize that reliability at the item level is crucial for compliance, operational efficiency, and patient safety." LiquidMate O stands as a testament to SAG's dedication to tackling the technical challenges faced by healthcare providers in medication administration.

Ready for Commercial Deployment

After extensive engineering efforts and validation processes, LiquidMate O is now prepared for commercial deployment. The product is expected to meet the rigorous requirements set forth by pharmaceutical environments for quality and operational adherence. SAG is initiating structured engagements with potential clients to discuss its implementation into their medication tracking systems, ensuring that they can leverage the benefits of this advanced RFID solution.

Conclusion

The launch of LiquidMate O signifies a turning point for the pharmaceutical industry as it navigates the complexities of drug supply chain security and medication safety. With its innovative design and proven high-performance capabilities, LiquidMate O promises to redefine how injectable medications are tracked, ultimately leading to enhanced operational efficiencies and better healthcare outcomes.